BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32667058)

  • 21. p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.
    Theodosakis N; Micevic G; Langdon CG; Ventura A; Means R; Stern DF; Bosenberg MW
    J Invest Dermatol; 2017 Oct; 137(10):2187-2196. PubMed ID: 28599981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphoinositide specific phospholipase Cγ1 inhibition-driven autophagy caused cell death in human lung adenocarcinoma A549 cells
    Lu X; Fu H; Chen R; Wang Y; Zhan Y; Song G; Hu T; Xia C; Tian X; Zhang B
    Int J Biol Sci; 2020; 16(8):1427-1440. PubMed ID: 32210730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway.
    Wu T; Wang MC; Jing L; Liu ZY; Guo H; Liu Y; Bai YY; Cheng YZ; Nan KJ; Liang X
    Drug Des Devel Ther; 2015; 9():6421-31. PubMed ID: 26715839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neferine augments therapeutic efficacy of cisplatin through ROS- mediated non-canonical autophagy in human lung adenocarcinoma (A549 cells).
    Kalai Selvi S; Vinoth A; Varadharajan T; Weng CF; Vijaya Padma V
    Food Chem Toxicol; 2017 May; 103():28-40. PubMed ID: 28223119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
    Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
    Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin.
    Dhar R; Basu A
    Int J Oncol; 2008 May; 32(5):1133-7. PubMed ID: 18425342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
    Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
    Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical Implications of RSK1-3 in Human Breast Cancer.
    Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG
    Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
    Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
    [No Abstract]   [Full Text] [Related]  

  • 31. Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
    Diao Y; Ma X; Min W; Lin S; Kang H; Dai Z; Wang X; Zhao Y
    Cancer Lett; 2016 Aug; 379(1):12-23. PubMed ID: 27195913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CCAAT-enhancer-binding protein beta activation of MMP-1 gene expression in SW1353 cells: independent roles of extracellular signal-regulated and p90/ribosomal S6 kinases.
    Petrella BL; Armstrong DA; Vincenti MP
    J Cell Physiol; 2011 Dec; 226(12):3349-54. PubMed ID: 21344389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on
    Mohiuddin M; Kasahara K
    Cancer Genomics Proteomics; 2021; 18(4):579-590. PubMed ID: 34183390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy.
    Zhang X; Cai L; Zhao S; Long J; Li J; Wu L; Su J; Zhang J; Tao J; Zhou J; Chen X; Peng C
    Biochem Pharmacol; 2019 Oct; 168():14-25. PubMed ID: 31207212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells.
    Kim JH; Jeong SJ; Kim B; Yun SM; Choi DY; Kim SH
    J Pineal Res; 2012 Mar; 52(2):244-52. PubMed ID: 22050627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.
    Pandey N; Tyagi G; Kaur P; Pradhan S; Rajam MV; Srivastava T
    Cell Physiol Biochem; 2020 Aug; 54(4):748-766. PubMed ID: 32809300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway.
    Achkar IW; Abdulrahman N; Al-Sulaiti H; Joseph JM; Uddin S; Mraiche F
    J Transl Med; 2018 Apr; 16(1):96. PubMed ID: 29642900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.
    van Jaarsveld MT; Blijdorp IC; Boersma AW; Pothof J; Mathijssen RH; Verweij J; Wiemer EA
    Eur J Cancer; 2013 Jan; 49(2):345-51. PubMed ID: 23041051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
    Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
    Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.